Abstract: 【Abstract】Objectives To investigate the efficacy and safety of paricalcitol in the treatment of hemodialysis patients complicated with secondary hyperparathyroidism (SHPT). Methods Eleven maintenance hemodialysis patients with SHPT treated in Beijing Sixth Hospital were enrolled in this study. Their initial dose of paricalcitol was 0.04-0.10 μg/kg. During the treatment period, serum levels of intact parathyroid hormone (iPTH), calcium, phosphorus, alkaline phosphatase (ALP) were monitored, and the score of visual analogue scale (VAS) was used to assess patient’s condition. The major efficacy parameter was the decrease of iPTH more than 50% of baseline value after 12 weeks of the treatment. The secondary efficacy parameters included the average range of iPTH below baseline value, the proportion of the patients with the iPTH level within 150～300pg/ml after 12 weeks of the treatment, as well as the incidence of adverse events at the end of the study. Results The average baseline iPTH level of the 11 patients was 1283.56 ± 443.71pg/ml. After 12
weeks of paricalcitol treatment, the average iPTH level decreased by 73.01% of the baseline value to 346.38±223.72 pg/ml (t=6.578, P＜0.001). In all of the 11 patients, the endpoint iPTH level decreased by more than 50% of the baseline value. At the endpoint of the study, iPTH levels reduced to 150-300pg/ml in 7 of the 11 patients and reached the compliance rate in 63.64% patients; serum calcium (t=2.952, P=0.088), phosphorus (t=1.305, P=0.206) and ALP (t= 1.513, P=0.145) had no significant differences compared to the baseline values in the 11 patients; VAS score was significantly lower than baseline value (t=15.976, P＜0.001). One patient developed hypercalcemia (serum calcium 2.64mmol/L). Conclusions This study confirmed that paricalcitol can effectively treat SHPT in hemodialysis patients. It can reduce serum iPTH level and the bone pain VAS score, without changes of serum calcium and phosphorus.

Key words: Paricalcitol, Hemodialysis patient, Secondary hyperparathyroidism